Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
Top Cited Papers
Open Access
Abstract
Background: About one‐tenth of patients with difficult‐to‐treat chronic rhinosinusitis with nasal polyps (CRSwNP) have comorbid non‐steroidal anti‐inflammatory drug‐exacerbated respiratory disease (NSAID‐ERD). Dupilumab, a fully human monoclonal antibody that blocks the shared interleukin (IL)‐4/IL‐13 receptor component, is an approved add‐on treatment in severe CRSwNP. This post hoc analysis evaluated dupilumab efficacy and safety in patients with CRSwNP with/without NSAID‐ERD.Methods: Data were pooled from the phase 3 SINUS‐24 and SINUS‐52 studies in adults with uncontrolled severe CRSwNP who received dupilumab 300 mg or placebo every 2 weeks. CRSwNP, nasal airflow, lung function, and asthma control outcomes at Week 24 were evaluated, and treatment–subgroup interactions were assessed for patients with and without NSAID‐ERD.Results: Of 724 patients, 204 (28.2%) had a diagnosis of NSAID‐ERD. At Week 24, least squares mean treatment differences demonstrated significant improvements in nasal polyp score, nasal congestion (NC), Lund–Mackay computed tomography, 22‐item Sinonasal Outcome Test (SNOT‐22), Total Symptom Score (TSS), rhinosinusitis severity visual analog scale, peak nasal inspiratory flow (PNIF), six‐item Asthma Control Questionnaire score, and improvement in smell with dupilumab versus placebo (all p < .0001) in patients with NSAID‐ERD. Treatment comparisons demonstrated significantly greater improvements with dupilumab in patients with versus without NSAID‐ERD for NC (p = .0044), SNOT‐22 (p = .0313), TSS (p = .0425), and PNIF (p = .0123).Conclusions: In patients with uncontrolled severe CRSwNP, dupilumab significantly improved objective measures and patient‐reported symptoms to a greater extent in the presence of comorbid NSAID‐ERD than without. Dupilumab was well tolerated in patients with/without NSAID‐ERD.Keywords
This publication has 35 references indexed in Scilit:
- Commonality of the IL-4/IL-13 pathway in atopic diseasesExpert Review of Clinical Immunology, 2017
- Is aspirin desensitization indicated for the treatment recalcitrant chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease?The Laryngoscope, 2016
- Eosinophils and Mast Cells in Aspirin-Exacerbated Respiratory DiseaseImmunology and Allergy Clinics of North America, 2016
- Chronic Rhinosinusitis with Nasal PolypsThe Journal of Allergy and Clinical Immunology: In Practice, 2016
- Aspirin-Exacerbated Respiratory Disease — New Prime SuspectsNew England Journal of Medicine, 2016
- Cytokines in Chronic Rhinosinusitis. Role in Eosinophilia and Aspirin-exacerbated Respiratory DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literatureJournal of Allergy and Clinical Immunology, 2015
- Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal miceProceedings of the National Academy of Sciences, 2014
- Precise and in situ genetic humanization of 6 Mb of mouse immunoglobulin genesProceedings of the National Academy of Sciences, 2014
- The relationship between historical aspirin-induced asthma and severity of asthma induced during oral aspirin challengesJournal of Allergy and Clinical Immunology, 2007